Abstract
Atherosclerosis is a systemic inflammatory disease leading to lipid-laden inflammatory lesions in the arterial walls that may destabilize and rupture. It is becoming clear that addressing the “classical” risk factors for atherosclerosis does not entirely reduce the risk of cardiovascular events. Novel biomarkers to be used in highthroughput assays are necessary for diagnosis, for determination of the residual risk and for monitoring the effects of the therapy. Since inflammation is a hallmark of atherosclerosis, tests for pro-inflammatory biomarkers have been introduced such as for hsCRP, fibrinogen and IL-6, with many more at different stages of development.
There has been a dearth of novel approaches for the diagnosis and management of atherosclerosis, reflected in a continuous reliance on LDL cholesterol as a proven target of investigations. To bring another perspective, here we briefly overview the accumulated epidemiological and sero-epidemiological evidence suggesting systemic infections as a component of atherosclerotic inflammations. We have shown that different individuals’ plaques are colonized with different bacterial species (atherosclerosis microbiota). Most of the time the pathogens are likely in an intracellular state, shielded from the host immune responses. There are controlled clinical trials and metaanalyses that corroborate the infections, specifically periodontal disease as a contributing risk factor of atherosclerosis. Infection-related markers, including transcriptome signatures, may identify latent infection patients with sub-clinical disease. Thus, the emerging infection- associated markers of inflammation could complement the existing ones and their use as companion diagnostics for atherosclerosis should stimulate the growing field of personalized medicine within cardiovascular diseases.
Keywords: Atherosclerosis, biomarkers, inflammation, infection.
Current Pharmaceutical Design
Title:Infection-Associated Biomarkers of Inflammation in Atherosclerosis
Volume: 21 Issue: 13
Author(s): Emil Kozarov, Kurt Huber and Johann Wojta
Affiliation:
Keywords: Atherosclerosis, biomarkers, inflammation, infection.
Abstract: Atherosclerosis is a systemic inflammatory disease leading to lipid-laden inflammatory lesions in the arterial walls that may destabilize and rupture. It is becoming clear that addressing the “classical” risk factors for atherosclerosis does not entirely reduce the risk of cardiovascular events. Novel biomarkers to be used in highthroughput assays are necessary for diagnosis, for determination of the residual risk and for monitoring the effects of the therapy. Since inflammation is a hallmark of atherosclerosis, tests for pro-inflammatory biomarkers have been introduced such as for hsCRP, fibrinogen and IL-6, with many more at different stages of development.
There has been a dearth of novel approaches for the diagnosis and management of atherosclerosis, reflected in a continuous reliance on LDL cholesterol as a proven target of investigations. To bring another perspective, here we briefly overview the accumulated epidemiological and sero-epidemiological evidence suggesting systemic infections as a component of atherosclerotic inflammations. We have shown that different individuals’ plaques are colonized with different bacterial species (atherosclerosis microbiota). Most of the time the pathogens are likely in an intracellular state, shielded from the host immune responses. There are controlled clinical trials and metaanalyses that corroborate the infections, specifically periodontal disease as a contributing risk factor of atherosclerosis. Infection-related markers, including transcriptome signatures, may identify latent infection patients with sub-clinical disease. Thus, the emerging infection- associated markers of inflammation could complement the existing ones and their use as companion diagnostics for atherosclerosis should stimulate the growing field of personalized medicine within cardiovascular diseases.
Export Options
About this article
Cite this article as:
Kozarov Emil, Huber Kurt and Wojta Johann, Infection-Associated Biomarkers of Inflammation in Atherosclerosis, Current Pharmaceutical Design 2015; 21 (13) . https://dx.doi.org/10.2174/1381612821666141129173343
DOI https://dx.doi.org/10.2174/1381612821666141129173343 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dynamic Role of Macrophage Sub Types on Development of Atherosclerosis
and Potential Use of Herbal Immunomodulators as Imminent
Therapeutic Strategy
Cardiovascular & Hematological Agents in Medicinal Chemistry Microarray: An Approach for Current Drug Targets
Current Drug Metabolism Nigella Sativa Improve Redox Homeostasis in Heart and Aorta of Diabetic Rat
Current Nutrition & Food Science Systemic Lupus Erythematosus: Correlation Between Immunodysregulation and Clinical Manifestations
Current Rheumatology Reviews Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD
Current Pharmaceutical Design Combination of Captopril with Gliclazide Decreases Vascular and Renal Complications and Improves Glycemic Control in Rats with Streptozotocin- Induced Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Patent Selections
Recent Patents on Cardiovascular Drug Discovery The Current Role of Statin Therapy in the Treatment of Atrial Fibrillation
Cardiovascular & Hematological Agents in Medicinal Chemistry Synergistic Antitumor Effect of 5-Fluorouracil Combined with Constituents from <i>Pleurospermum lindleyanum</i> in Hepatocellular Carcinoma SMMC-7721 Cells
Anti-Cancer Agents in Medicinal Chemistry Editorial (Thematic Issue: Renal and Urological Diseases of the Newborn)
Current Pediatric Reviews Targeting Apelinergic System in Cardiometabolic Disease
Current Drug Targets Evaluation of Gene and Cell-Based Therapies for Cardiac Regeneration
Current Stem Cell Research & Therapy Plant Polyphenols and Oral Health: Old Phytochemicals for New Fields
Current Medicinal Chemistry New Clinical Perspectives of Hypolipidemic Drug Therapy in Severe Hypercholesterolemia
Current Medicinal Chemistry Steerable Sheath Technology in the Ablation of Atrial Fibrillation
Recent Patents on Cardiovascular Drug Discovery Resveratrol, A Neuroprotective Supplement for Alzheimer's Disease
Current Pharmaceutical Design Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
Current Pharmaceutical Design Myocardial Infarction Following Atherosclerosis in Murine Models
Current Drug Targets IP6 (Inositol Hexaphosphate) as a Signaling Molecule
Current Signal Transduction Therapy Editorial [Hot topic: Infective Endocarditis (Guest Editor: Ioannis Starakis)]
Infectious Disorders - Drug Targets